## Benedict Maliakkal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12097315/publications.pdf

Version: 2024-02-01

42 papers

2,661 citations

304743 22 h-index 276875
41
g-index

42 all docs 42 docs citations

times ranked

42

3007 citing authors

#	Article	IF	CITATIONS
1	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60, 250-256.	7.3	456
2	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. Journal of Hepatology, 2017, 67, 263-271.	3.7	261
3	New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. Gastroenterology, 2013, 145, 1280-1288.e1.	1.3	221
4	NACSELD acuteâ€onâ€chronic liver failure (NACSELDâ€ACLF) score predicts 30â€day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67, 2367-2374.	7.3	197
5	The 3â€month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology, 2016, 64, 200-208.	7.3	189
6	Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology, 2018, 67, 514-523.	7.3	124
7	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clinical Gastroenterology and Hepatology, 2017, 15, 565-574.e4.	4.4	105
8	Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience. American Journal of Transplantation, 2019, 19, 3046-3057.	4.7	103
9	Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infectious Diseases, The, 2017, 17, 735-744.	9.1	91
10	High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology, 2016, 151, 651-659.e1.	1.3	90
11	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. American Journal of Gastroenterology, 2018, 113, 556-563.	0.4	87
12	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. Journal of Hepatology, 2015, 62, 286-293.	3.7	86
13	A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis. Hepatology, 2017, 65, 217-224.	7.3	74
14	Living Donor and Deceased Donor Liver Transplantation for Autoimmune and Cholestatic Liver Diseases—An Analysis of the UNOS Database. Journal of Gastrointestinal Surgery, 2010, 14, 1362-1369.	1.7	73
15	Outcomes After Listing for Liver Transplant in Patients With Acuteâ€onâ€Chronic Liver Failure: The Multicenter North American Consortium for the Study of Endâ€Stage Liver Disease Experience. Liver Transplantation, 2019, 25, 571-579.	2.4	53
16	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1339.	0.4	44
17	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100.	0.4	41
18	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multiâ€centre cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1518-1527.	3.7	40

#	Article	IF	CITATIONS
19	Comparative Analysis of Outcomes in Living and Deceased Donor Liver Transplants for Primary Sclerosing Cholangitis. Journal of Gastrointestinal Surgery, 2009, 13, 1480-1486.	1.7	37
20	Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes. American Journal of Kidney Diseases, 2021, 77, 739-747.e1.	1.9	29
21	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. Liver Transplantation, 2020, 26, 68-79.	2.4	26
22	A cut-off serum creatinine value of 1.5 mg/dl for AKI – To be or not to be. Journal of Hepatology, 2015, 62, 741-743.	3.7	25
23	Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. Journal of Clinical and Experimental Hepatology, 2020, 10, 245-254.	0.9	24
24	Outcomes of Liver Transplant Recipients With Acute-on-Chronic Liver Failure Based on EASL-CLIF Consortium Definition: A Single-center Study. Transplantation Direct, 2020, 6, e544.	1.6	22
25	Novel use of EUS to successfully treat bleeding parastomal varices with N-butyl-2-cyanoacrylate. Gastrointestinal Endoscopy, 2014, 79, 1007-1008.	1.0	21
26	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2019, 114, 599-606.	0.4	17
27	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Digestive Diseases and Sciences, 2020, 65, 2571-2579.	2.3	17
28	Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. American Journal of Gastroenterology, 2021, 116, 336-346.	0.4	17
29	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. Digestive Diseases and Sciences, 2021, 66, 3612-3618.	2.3	15
30	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2021, 19, 1661-1669.e2.	4.4	14
31	Association between postâ€transplant donorâ€specific antibodies and recipient outcomes in simultaneous liver–kidney transplant recipients: singleâ€center, cohort study. Transplant International, 2020, 33, 202-215.	1.6	12
32	Transplantation of liver from hepatitis C–infected donors to hepatitis C RNA–negative recipients: Histological and virologic outcome. Clinical Transplantation, 2021, 35, e14281.	1.6	8
33	African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians. European Journal of Gastroenterology and Hepatology, 2021, 33, 388-398.	1.6	8
34	Nutrition in Chronic Liver Disease. Current Treatment Options in Gastroenterology, 2019, 17, 602-618.	0.8	7
35	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 565-572.e5.	4.4	7
36	Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol. Nephron, 2020, 144, 126-137.	1.8	5

#	Article	IF	CITATIONS
37	Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2020, 11, e00165.	2.5	4
38	Longitudinal Renal Function in Liver Transplant Recipients With Acute-on-Chronic Liver Failure. Clinical and Translational Gastroenterology, 2020, 11, e00185.	2.5	4
39	Factors associated with hepatitis C antibody seroconversion after transplantation of kidneys from hepatitis C infected donors to hepatitis C naÃ-ve recipients. Renal Failure, 2020, 42, 767-775.	2.1	3
40	A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction. PLoS ONE, 2020, 15, e0232006.	2.5	2
41	Effect of opioid treatment on clinical outcomes among cirrhotic patients in the United States. Clinical Transplantation, 2020, 34, e13845.	1.6	2
42	Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation. Baylor University Medical Center Proceedings, 2020, 33, 256-257.	0.5	0